Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Regeneron Pharmaceuticals Inc (REGN) Faces Trouble With Eylea Amid Strong Sales

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has recently released its third quarter earnings report, with Eylea (aflibercept) sales being the highlight.

Eylea Sales Performance

Eylea has been one of the main drivers of growth for Regeneron over the past couple of years. During the third quarter, net product sales of Eylea have surged 16% year-over-year to $854 million from $734 million.

However, to continue this momentum, the company needs to overcome a major challenge first. Many patients do not consult retinal specialists who often prescribe Eylea. Instead, they consult ophthalmologists to get laser therapy without understanding that Eylea is a potential alternative treatment.

bogdanhoda/Shutterstock.com

bogdanhoda/Shutterstock.com

Q3 Financial Results

For the period, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) had a total revenue of $1.22 billion, up by 7% year-over-year from $1.14 billion. Net product sales, on the other hand, have advanced year-over-year to $857 million from $738 million.

Along with the strong sales performance of Eylea, Praluent (alirocumab) sales have also surged to $38 million from $4 million.

Net income came in at $265 million, up by 26% year-over-year from $210 million. This indicates a diluted earnings per share (EPS) of $2.27 for the third quarter.

Research and Development Update

The company has also provided updates regarding its product pipeline clinical development programs. Presently, 16 candidates, which include Eylea and 15 human monoclonal antibodies, are undergoing various clinical trials.

Dupixent (dupilumab), a human monoclonal antibody blocking signaling of IL-4 and IL-13, is currently being assessed for asthma, atopic dermatitis, eosinophilic esophagitis, and nasal polyps.

Nesvacumab, a human monoclonal antibody co-formulated with aflibercept for intravitreal injection, is currently being assessed for the treatment of patients with diabetic macular edema (DME) under the Phase 2 RUBY clinical trial.

Rinucumab, a human monoclonal antibody co-formulated with aflibercept for intravitreal injection, is currently being assessed for the treatment of patients with neovascular age-related macular degeneration (wet AMD) under the CAPELLA clinical development program.

Sarilumab, a human monoclonal antibody targeting IL-6R for rheumatoid arthritis (RA), is currently being assessed under the Phase 3 SARIL-RA clinical trial.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has closed at $365.39, up by 7.09%, on Monday.

Follow Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Trade (NASDAQ:REGN) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

Loading Comments...